“I expect that to hit midyear, and that's another great opportunity.”

In context

“super. In terms of market share, I think TriClip here is now clearly the preferred option. Safety plays a major role in deciding what to choose and, you know, the safety record here is pretty excellent, not just in the clinical trials, but also in the real world. So I expect this to annualize at around a quarter of a billion dollars but really gaining a lot of momentum as we exit the year for a couple of things. One, we were launching a next generation of TriClip, and it's going to further enhance the ease of use. It simplifies all of the prep work. I've been to a couple of cases, and it's not a pain point, but it's just a nice thing to have to be able to reduce some of that device prep work before. So I think the team's done a really good job there. We also saw the CMS publish their end. I expect that to hit midyear, and that's another great opportunity. But the two-year data, I think, was pretty significant at ACC and really showed, you know, I know there's a lot of question marks about, you know, the endpoint a year ago, but, you know, that really was empowered for one year. You know, and you're starting to see now the benefits on that hard data come out. I think that plays a huge role when you got the safety and you got the hard endpoint. So all in all, I think the structural heart business is going to continue to be in these teen growth rates. And we got opportunities for international expansion too. So and then plus all the R&D work that's ongoing, whether it's balloon expandable, you know, next generation MitraClip, next generation TriClip, next generation Angulet. I mean, it's just really stacked up, and the team's doing a good job”